Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Kestra Medical Technologies (KMTS) EBITDA (2024 - 2026)

Kestra Medical Technologies (KMTS) has disclosed EBITDA for 3 consecutive years, with -$34.8 million as the latest value for Q1 2026.

  • Quarterly EBITDA fell 68.75% to -$34.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$143.6 million through Jan 2026, down 82.91% year-over-year, with the annual reading at -$106.4 million for FY2025, 25.06% down from the prior year.
  • EBITDA for Q1 2026 was -$34.8 million at Kestra Medical Technologies, down from -$31.8 million in the prior quarter.
  • The five-year high for EBITDA was -$18.4 million in Q3 2024, with the low at -$48.2 million in Q2 2025.
  • Average EBITDA over 3 years is -$26.9 million, with a median of -$20.6 million recorded in 2025.
  • Peak annual rise in EBITDA hit 3.28% in 2025, while the deepest fall reached 136.93% in 2025.
  • Over 3 years, EBITDA stood at -$19.1 million in 2024, then tumbled by 65.96% to -$31.8 million in 2025, then fell by 9.48% to -$34.8 million in 2026.
  • According to Business Quant data, EBITDA over the past three periods came in at -$34.8 million, -$31.8 million, and -$28.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.